Stockreport

La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis

La Jolla Pharmaceutical Company  (LJPC) 
Last la jolla pharmaceutical company earnings: 3/2 08:30 am Check Earnings Report
US:NASDAQ Investor Relations: lajollapharmaceutical.com/investor-relations
PDF - Treatment with LJPC-401 Resulted in Statistically Significant Reduction in Change in Transferrin Saturation (TSAT), the Primary Efficacy Endpoint of the Study, and Fre [Read more]